Cargando…

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy

We report incidence and deep molecular characteristics of lineage switch in 182 pediatric patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were treated with blinatumomab. We documented six cases of lineage switch that occurred after or during blinatumomab exposure. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Semchenkova, Alexandra, Mikhailova, Ekaterina, Komkov, Alexander, Gaskova, Marina, Abasov, Ruslan, Matveev, Evgenii, Kazanov, Marat, Mamedov, Ilgar, Shmitko, Anna, Belova, Vera, Miroshnichenkova, Anna, Illarionova, Olga, Olshanskaya, Yulia, Tsaur, Grigory, Verzhbitskaya, Tatiana, Ponomareva, Natalia, Bronin, Gleb, Kondratchik, Konstantin, Fechina, Larisa, Diakonova, Yulia, Vavilova, Liudmila, Myakova, Natalia, Novichkova, Galina, Maschan, Alexey, Maschan, Michael, Zerkalenkova, Elena, Popov, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999738/
https://www.ncbi.nlm.nih.gov/pubmed/35409391
http://dx.doi.org/10.3390/ijms23074019
_version_ 1784685261418921984
author Semchenkova, Alexandra
Mikhailova, Ekaterina
Komkov, Alexander
Gaskova, Marina
Abasov, Ruslan
Matveev, Evgenii
Kazanov, Marat
Mamedov, Ilgar
Shmitko, Anna
Belova, Vera
Miroshnichenkova, Anna
Illarionova, Olga
Olshanskaya, Yulia
Tsaur, Grigory
Verzhbitskaya, Tatiana
Ponomareva, Natalia
Bronin, Gleb
Kondratchik, Konstantin
Fechina, Larisa
Diakonova, Yulia
Vavilova, Liudmila
Myakova, Natalia
Novichkova, Galina
Maschan, Alexey
Maschan, Michael
Zerkalenkova, Elena
Popov, Alexander
author_facet Semchenkova, Alexandra
Mikhailova, Ekaterina
Komkov, Alexander
Gaskova, Marina
Abasov, Ruslan
Matveev, Evgenii
Kazanov, Marat
Mamedov, Ilgar
Shmitko, Anna
Belova, Vera
Miroshnichenkova, Anna
Illarionova, Olga
Olshanskaya, Yulia
Tsaur, Grigory
Verzhbitskaya, Tatiana
Ponomareva, Natalia
Bronin, Gleb
Kondratchik, Konstantin
Fechina, Larisa
Diakonova, Yulia
Vavilova, Liudmila
Myakova, Natalia
Novichkova, Galina
Maschan, Alexey
Maschan, Michael
Zerkalenkova, Elena
Popov, Alexander
author_sort Semchenkova, Alexandra
collection PubMed
description We report incidence and deep molecular characteristics of lineage switch in 182 pediatric patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were treated with blinatumomab. We documented six cases of lineage switch that occurred after or during blinatumomab exposure. Therefore, lineage conversion was found in 17.4% of all resistance cases (4/27) and 3.2% of relapses (2/63). Half of patients switched completely from BCP-ALL to CD19-negative acute myeloid leukemia, others retained CD19-positive B-blasts and acquired an additional CD19-negative blast population: myeloid or unclassifiable. Five patients had KMT2A gene rearrangements; one had TCF3::ZNF384 translocation. The presented cases showed consistency of gene rearrangements and fusion transcripts across initially diagnosed leukemia and lineage switch. In two of six patients, the clonal architecture assessed by IG/TR gene rearrangements was stable, while in others, loss of clones or gain of new clones was noted. KMT2A-r patients demonstrated very few additional mutations, while in the TCF3::ZNF384 case, lineage switch was accompanied by a large set of additional mutations. The immunophenotype of an existing leukemia sometimes changes via different mechanisms and with different additional molecular changes. Careful investigation of all BM compartments together with all molecular –minimal residual disease studies can lead to reliable identification of lineage switch.
format Online
Article
Text
id pubmed-8999738
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89997382022-04-12 Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy Semchenkova, Alexandra Mikhailova, Ekaterina Komkov, Alexander Gaskova, Marina Abasov, Ruslan Matveev, Evgenii Kazanov, Marat Mamedov, Ilgar Shmitko, Anna Belova, Vera Miroshnichenkova, Anna Illarionova, Olga Olshanskaya, Yulia Tsaur, Grigory Verzhbitskaya, Tatiana Ponomareva, Natalia Bronin, Gleb Kondratchik, Konstantin Fechina, Larisa Diakonova, Yulia Vavilova, Liudmila Myakova, Natalia Novichkova, Galina Maschan, Alexey Maschan, Michael Zerkalenkova, Elena Popov, Alexander Int J Mol Sci Article We report incidence and deep molecular characteristics of lineage switch in 182 pediatric patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were treated with blinatumomab. We documented six cases of lineage switch that occurred after or during blinatumomab exposure. Therefore, lineage conversion was found in 17.4% of all resistance cases (4/27) and 3.2% of relapses (2/63). Half of patients switched completely from BCP-ALL to CD19-negative acute myeloid leukemia, others retained CD19-positive B-blasts and acquired an additional CD19-negative blast population: myeloid or unclassifiable. Five patients had KMT2A gene rearrangements; one had TCF3::ZNF384 translocation. The presented cases showed consistency of gene rearrangements and fusion transcripts across initially diagnosed leukemia and lineage switch. In two of six patients, the clonal architecture assessed by IG/TR gene rearrangements was stable, while in others, loss of clones or gain of new clones was noted. KMT2A-r patients demonstrated very few additional mutations, while in the TCF3::ZNF384 case, lineage switch was accompanied by a large set of additional mutations. The immunophenotype of an existing leukemia sometimes changes via different mechanisms and with different additional molecular changes. Careful investigation of all BM compartments together with all molecular –minimal residual disease studies can lead to reliable identification of lineage switch. MDPI 2022-04-05 /pmc/articles/PMC8999738/ /pubmed/35409391 http://dx.doi.org/10.3390/ijms23074019 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Semchenkova, Alexandra
Mikhailova, Ekaterina
Komkov, Alexander
Gaskova, Marina
Abasov, Ruslan
Matveev, Evgenii
Kazanov, Marat
Mamedov, Ilgar
Shmitko, Anna
Belova, Vera
Miroshnichenkova, Anna
Illarionova, Olga
Olshanskaya, Yulia
Tsaur, Grigory
Verzhbitskaya, Tatiana
Ponomareva, Natalia
Bronin, Gleb
Kondratchik, Konstantin
Fechina, Larisa
Diakonova, Yulia
Vavilova, Liudmila
Myakova, Natalia
Novichkova, Galina
Maschan, Alexey
Maschan, Michael
Zerkalenkova, Elena
Popov, Alexander
Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
title Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
title_full Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
title_fullStr Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
title_full_unstemmed Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
title_short Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
title_sort lineage conversion in pediatric b-cell precursor acute leukemia under blinatumomab therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999738/
https://www.ncbi.nlm.nih.gov/pubmed/35409391
http://dx.doi.org/10.3390/ijms23074019
work_keys_str_mv AT semchenkovaalexandra lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT mikhailovaekaterina lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT komkovalexander lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT gaskovamarina lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT abasovruslan lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT matveevevgenii lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT kazanovmarat lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT mamedovilgar lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT shmitkoanna lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT belovavera lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT miroshnichenkovaanna lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT illarionovaolga lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT olshanskayayulia lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT tsaurgrigory lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT verzhbitskayatatiana lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT ponomarevanatalia lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT broningleb lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT kondratchikkonstantin lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT fechinalarisa lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT diakonovayulia lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT vavilovaliudmila lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT myakovanatalia lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT novichkovagalina lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT maschanalexey lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT maschanmichael lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT zerkalenkovaelena lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy
AT popovalexander lineageconversioninpediatricbcellprecursoracuteleukemiaunderblinatumomabtherapy